Claris Bio

Drug Discovery · Jersey City, NJ · Founded 2018 · Privately Held (backing)

Developer of a topical formulation technology designed to treat orphan ophthalmic disorders. Claris Bio is based in Jersey City, NJ and was founded in 2018. It was valued at $163 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $154 million across 1 recorded round; the latest was a $54.5 million Series A in Jan 2024.

PMV mark · valuation
$163.4M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$153.6M
Last round
Later Stage VC (Series A)
Jan 2024
What is Claris Bio worth?
$163.4MPrivateMarketView mark · Oct 2026

Valued at $163.4M at its later-stage round, Nov 2025. Nothing has traded since.

Free account
More of Claris Bio with a free account
  • ·Watch Claris Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Claris Bio funding history

1 rounds
DateRoundRaisedPost-money
Jan 2024Later Stage VC (Series A)$54.5M▮
Unlock post-money valuations

Membership and data by Private Market View

Claris Bio valuation

Claris Bio was valued at $163 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Claris Bio raised?

Claris Bio has raised $154 million in total; 1 of its rounds is on record. The largest on record was a $54.5 million Series A in Jan 2024.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Cambrian Bio ($180 million), Gordian Biotechnology ($170 million) and Delix Therapeutics ($156 million).

How Claris Bio's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Claris Bio, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Claris Bio

What is Claris Bio worth?
Claris Bio is valued at $163.4M as of Oct 2026. Valued at $163.4M at its later-stage round, Nov 2025. Nothing has traded since.
How much has Claris Bio raised?
Claris Bio has raised $153.6M in total funding across 1 recorded rounds.
When did Claris Bio last raise?
Claris Bio last raised in Jan 2024 (Later Stage VC (Series A)), raising $54.5M.